🔎 Trials Near Me

Beranda › Kanker Paru Non-Sel Kecil › Hawaii › Honolulu

Uji klinis Kanker Paru Non-Sel Kecil di Honolulu, HI

10 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Honolulu (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Menerima pesertaFase 3
  • Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu
  • Queen's Cancer Cenrer - POB I, Honolulu
  • Queen's Medical Center, Honolulu
  • dan 5 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04267848

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Menerima pesertaFase 3
  • Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu
  • Queen's Cancer Cenrer - POB I, Honolulu
  • Queen's Medical Center, Honolulu
  • dan 4 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06498635

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Menerima pesertaFase 3
  • Kaiser Permanente Moanalua Medical Center /ID# 238363, Honolulu
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT04928846

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Menerima pesertaFase 2
  • Kaiser Permanente Moanalua Medical Center /ID# 272916, Honolulu
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06568939

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Menerima pesertaFase 3
  • The Queens Medical Center, Honolulu
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT06899126

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Menerima pesertaFase 2
  • Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu
  • Queen's Cancer Cenrer - POB I, Honolulu
  • Queen's Medical Center, Honolulu
  • dan 2 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Menerima pesertaFase 2
  • Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu
  • Queen's Cancer Cenrer - POB I, Honolulu
  • Queen's Medical Center, Honolulu
  • dan 6 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT06116682

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Menerima peserta
  • Spark M. Matsunaga VA Medical Center, Honolulu
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Apr 2026 · NCT05297734

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Menerima pesertaStudi observasional
  • Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu
  • Queen's Cancer Center - POB I, Honolulu
  • Queen's Medical Center, Honolulu
  • dan 9 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT06418204

GEMINI-NSCLC: NSCLC Biomarker Study

Menerima pesertaStudi observasional
  • Hawaii Cancer Care, Honolulu
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Feb 2026 · NCT05236114

Uji klinis Kanker Paru Non-Sel Kecil di kota lain

Studi lain di Honolulu

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.